vs

Side-by-side financial comparison of AXCELIS TECHNOLOGIES INC (ACLS) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.

AXCELIS TECHNOLOGIES INC is the larger business by last-quarter revenue ($238.3M vs $142.0M, roughly 1.7× Oncology Institute, Inc.). AXCELIS TECHNOLOGIES INC runs the higher net margin — 14.4% vs -5.3%, a 19.7% gap on every dollar of revenue. On growth, Oncology Institute, Inc. posted the faster year-over-year revenue change (41.6% vs -5.6%). Oncology Institute, Inc. produced more free cash flow last quarter ($2.2M vs $-8.9M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs -2.8%).

Axcelis Technologies, Inc. is an American company engaging in the design, manufacture, and servicing of capital equipment for the semiconductor manufacturing industry worldwide. It produces ion implantation systems, including high and medium current implanters, and high energy implanters, and curing systems used in the fabrication of semiconductor chips. The company was incorporated in 1995 and is headquartered in Beverly, Massachusetts, United States.

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

ACLS vs TOI — Head-to-Head

Bigger by revenue
ACLS
ACLS
1.7× larger
ACLS
$238.3M
$142.0M
TOI
Growing faster (revenue YoY)
TOI
TOI
+47.2% gap
TOI
41.6%
-5.6%
ACLS
Higher net margin
ACLS
ACLS
19.7% more per $
ACLS
14.4%
-5.3%
TOI
More free cash flow
TOI
TOI
$11.1M more FCF
TOI
$2.2M
$-8.9M
ACLS
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
-2.8%
ACLS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACLS
ACLS
TOI
TOI
Revenue
$238.3M
$142.0M
Net Profit
$34.3M
$-7.5M
Gross Margin
47.0%
Operating Margin
15.2%
-4.9%
Net Margin
14.4%
-5.3%
Revenue YoY
-5.6%
41.6%
Net Profit YoY
-31.3%
43.0%
EPS (diluted)
$1.11
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLS
ACLS
TOI
TOI
Q4 25
$238.3M
$142.0M
Q3 25
$213.6M
$136.6M
Q2 25
$194.5M
$119.8M
Q1 25
$192.6M
$104.4M
Q4 24
$252.4M
$100.3M
Q3 24
$256.6M
$99.9M
Q2 24
$256.5M
$98.6M
Q1 24
$252.4M
$94.7M
Net Profit
ACLS
ACLS
TOI
TOI
Q4 25
$34.3M
$-7.5M
Q3 25
$26.0M
$-16.5M
Q2 25
$31.4M
$-17.0M
Q1 25
$28.6M
$-19.6M
Q4 24
$50.0M
$-13.2M
Q3 24
$48.6M
$-16.1M
Q2 24
$50.9M
$-15.5M
Q1 24
$51.6M
$-19.9M
Gross Margin
ACLS
ACLS
TOI
TOI
Q4 25
47.0%
Q3 25
41.6%
Q2 25
44.9%
Q1 25
46.1%
Q4 24
46.0%
Q3 24
42.9%
Q2 24
43.8%
Q1 24
46.0%
Operating Margin
ACLS
ACLS
TOI
TOI
Q4 25
15.2%
-4.9%
Q3 25
11.7%
-5.9%
Q2 25
14.9%
-9.4%
Q1 25
15.1%
-9.5%
Q4 24
21.6%
-11.9%
Q3 24
18.3%
-13.9%
Q2 24
20.6%
-16.6%
Q1 24
22.4%
-19.0%
Net Margin
ACLS
ACLS
TOI
TOI
Q4 25
14.4%
-5.3%
Q3 25
12.2%
-12.1%
Q2 25
16.1%
-14.2%
Q1 25
14.8%
-18.8%
Q4 24
19.8%
-13.1%
Q3 24
18.9%
-16.1%
Q2 24
19.8%
-15.7%
Q1 24
20.4%
-21.0%
EPS (diluted)
ACLS
ACLS
TOI
TOI
Q4 25
$1.11
$-0.04
Q3 25
$0.83
$-0.14
Q2 25
$0.98
$-0.15
Q1 25
$0.88
$-0.21
Q4 24
$1.54
$-0.14
Q3 24
$1.49
$-0.18
Q2 24
$1.55
$-0.17
Q1 24
$1.57
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLS
ACLS
TOI
TOI
Cash + ST InvestmentsLiquidity on hand
$374.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.0B
$-15.7M
Total Assets
$1.4B
$164.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLS
ACLS
TOI
TOI
Q4 25
$374.3M
Q3 25
$449.6M
Q2 25
$549.8M
Q1 25
$587.1M
Q4 24
$571.3M
Q3 24
$579.4M
Q2 24
$548.3M
$9.9M
Q1 24
$530.2M
$29.8M
Stockholders' Equity
ACLS
ACLS
TOI
TOI
Q4 25
$1.0B
$-15.7M
Q3 25
$1.0B
$-12.3M
Q2 25
$1.0B
$-9.0M
Q1 25
$1.0B
$5.1M
Q4 24
$1.0B
$3.6M
Q3 24
$975.6M
$15.5M
Q2 24
$934.9M
$29.2M
Q1 24
$901.7M
$41.3M
Total Assets
ACLS
ACLS
TOI
TOI
Q4 25
$1.4B
$164.7M
Q3 25
$1.4B
$163.6M
Q2 25
$1.3B
$159.8M
Q1 25
$1.3B
$164.0M
Q4 24
$1.3B
$172.7M
Q3 24
$1.3B
$179.2M
Q2 24
$1.3B
$179.6M
Q1 24
$1.3B
$204.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLS
ACLS
TOI
TOI
Operating Cash FlowLast quarter
$-6.6M
$3.2M
Free Cash FlowOCF − Capex
$-8.9M
$2.2M
FCF MarginFCF / Revenue
-3.7%
1.5%
Capex IntensityCapex / Revenue
1.0%
0.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$107.0M
$-27.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLS
ACLS
TOI
TOI
Q4 25
$-6.6M
$3.2M
Q3 25
$45.4M
$-12.6M
Q2 25
$39.7M
$-10.2M
Q1 25
$39.8M
$-5.0M
Q4 24
$12.8M
$4.2M
Q3 24
$45.7M
$819.0K
Q2 24
$40.1M
$-15.7M
Q1 24
$42.2M
$-15.9M
Free Cash Flow
ACLS
ACLS
TOI
TOI
Q4 25
$-8.9M
$2.2M
Q3 25
$43.3M
$-13.2M
Q2 25
$37.7M
$-11.4M
Q1 25
$34.8M
$-5.3M
Q4 24
$8.1M
$2.4M
Q3 24
$41.8M
$417.0K
Q2 24
$38.1M
$-17.5M
Q1 24
$40.6M
$-16.5M
FCF Margin
ACLS
ACLS
TOI
TOI
Q4 25
-3.7%
1.5%
Q3 25
20.3%
-9.7%
Q2 25
19.4%
-9.5%
Q1 25
18.1%
-5.1%
Q4 24
3.2%
2.4%
Q3 24
16.3%
0.4%
Q2 24
14.8%
-17.7%
Q1 24
16.1%
-17.4%
Capex Intensity
ACLS
ACLS
TOI
TOI
Q4 25
1.0%
0.7%
Q3 25
0.9%
0.4%
Q2 25
1.0%
1.0%
Q1 25
2.6%
0.3%
Q4 24
1.8%
1.8%
Q3 24
1.5%
0.4%
Q2 24
0.8%
1.9%
Q1 24
0.6%
0.6%
Cash Conversion
ACLS
ACLS
TOI
TOI
Q4 25
-0.19×
Q3 25
1.75×
Q2 25
1.27×
Q1 25
1.39×
Q4 24
0.26×
Q3 24
0.94×
Q2 24
0.79×
Q1 24
0.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACLS
ACLS

Products$224.6M94%
Services$13.7M6%

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

Related Comparisons